11 October 2019

Consortium intensifies its focus on future access

In September the Levo-Praziquantel 150mg Phase 3 trial was initiated in Kenya. With the project moving towards registration, the Consortium is intensifying its engagement with key stakeholders, globally, regionally and nationally.

In August at the 7th Tokyo International Conference on African Development (TICAD), the GHIT Fund side event reception was focused on the fight against Neglected Tropical Diseases (NTDs) , tuberculosis, and malaria. During the reception Merck and Astellas highlighted the current status of Levo-Praziquantel development program and the potential impact of the product.

September turned out to be a busy month with SCI and Merck attending the 10th Neglected Tropical Diseases (NTDs) NGO Network meeting and 11th European Congress on Tropical Medicine and International Health, respectively. Together with Astellas, both partners were also representing the Consortium at the UNDP/ADP meeting in New York. Apart from sharing the Consortium story, these meetings also turned out to be to be excellent opportunities to exchange thoughts on future access with key stakeholders.

Apart from attending these globally oriented meetings, the Consortium is well aware of continuously ensuring the support of endemic country stakeholders. Senior representatives of the Consortium visited the trial site in Kenya and engaged with representatives of the ministry of health in Cote d’Ivoire and Kenya. Program Lead Dr Elly Kourany-Lefoll was invited to join the 2nd Annual General Meeting of the TIBA partnership, with whom the Consortium has a close relationship.

Until the end of the year, the Consortium will continue its external outreach and has planned to attend a dedicated German-Japan symposium at the  World Health Summit in Berlin (25 Oct), the Joint UNICEF-UNFPA-WHO Meeting 2019 in Copenhagen (2-5 Dec) and the GHIT R&D Forum 2019 in Tokyo (6 Dec).

If you happen to be there as well, and would like to know more, simply reach out to us.